G1 Therapeutics to Provide Third Quarter 2020 Corporate and Financial Update on November 4, 2020
G1 Therapeutics, a clinical-stage oncology company, announced a webcast and conference call on November 4, 2020, at 4:30 p.m. ET to provide a corporate and financial update for Q3 2020. Interested participants can access the call by dialing the provided numbers and using the conference code. G1 Therapeutics focuses on developing next-generation therapies for cancer, including trilaciclib and rintodestrant, and has out-licensed its oral CDK4/6 inhibitor, lerociclib, in 2020. For more details, visit their website.
- Company is advancing novel cancer therapies, aiming to improve patient outcomes.
- G1 has successfully out-licensed its oral CDK4/6 inhibitor, potentially expanding its market reach.
- None.
RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2020 on Wednesday, November 4, 2020 at 4:30 p.m. ET.
The live call may be accessed by dialing 866-763-6020 (domestic) or 210-874-7713 (international) and entering the conference code: 6634419. The live and archived webcast will be available on the Events & Presentations page of the G1 website.
About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies: trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy; rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.
G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
Contact:
Jeff Macdonald
Senior Director, Investor Relations & Corporate Communications
919-907-1944
jmacdonald@g1therapeutics.com
FAQ
When is G1 Therapeutics' Q3 2020 financial update call?
How can I access G1 Therapeutics' conference call?
What therapies is G1 Therapeutics developing?
What rights did G1 Therapeutics out-license in 2020?
